Phase 2 comparison of a novel ammonia scavenging agent with sodium phenylbutyrate in patients with urea cycle disorders: safety, pharmacokinetics and ammonia control.
Glycerol phenylbutyrate (glyceryl tri (4-phenylbutyrate)) (GPB) is being studied as an alternative to sodium phenylbutyrate (NaPBA) for the treatment of urea cycle disorders (UCDs). This phase 2 study explored the hypothesis that GPB offers similar safety and ammonia control as NaPBA, which is currently approved as adjunctive therapy in the chronic management of UCDs, and examined correlates of 24-h blood ammonia.


METHODS
An open-label, fixed sequence switch-over study was conducted in adult UCD patients taking maintenance NaPBA. Blood ammonia and blood and urine metabolites were compared after 7 days (steady state) of TID dosing on either drug, both dosed to deliver the same amount of phenylbutyric acid (PBA).


RESULTS
Ten subjects completed the study. Adverse events were comparable for the two drugs; 2 subjects experienced hyperammonemic events on NaPBA while none occurred on GPB. Ammonia values on GPB were approximately 30% lower than on NaPBA (time-normalized AUC=26.2 vs. 38.4 micromol/L; Cmax=56.3 vs. 79.1 micromol/L; not statistically significant), and GPB achieved non-inferiority to NaPBA with respect to ammonia (time-normalized AUC) by post hoc analysis. Systemic exposure (AUC(0-24)) to PBA on GPB was 27% lower than on NaPBA (540 vs. 739 microgh/mL), whereas exposure to phenylacetic acid (PAA) (575 vs. 596 microg h/mL) and phenylacetylglutamine (PAGN) (1098 vs. 1133 microg h/mL) were similar. Urinary PAGN excretion accounted for approximately 54% of PBA administered for both NaPBA and GPB; other metabolites accounted for <1%. Intact GPB was generally undetectable in blood and urine. Blood ammonia correlated strongly and inversely with urinary PAGN (r=-0.82; p<0.0001) but weakly or not at all with blood metabolite levels.


CONCLUSIONS
Safety and ammonia control with GPB appear at least equal to NaPBA. Urinary PAGN, which is stoichiometrically related to nitrogen scavenging, may be a useful biomarker for both dose selection and adjustment for optimal control of venous ammonia.
Lee
Brendan
B
Baylor College of Medicine, Houston, TX, USA. blee@bcm.tmc.edu
Rhead
William
W
Diaz
George A
GA
Scharschmidt
Bruce F
BF
Mian
Asad
A
Shchelochkov
Oleg
O
Marier
J F
JF
Beliveau
Martin
M
Mauney
Joseph
J
Dickinson
Klara
K
Martinez
Antonia
A
Gargosky
Sharron
S
Mokhtarani
Masoud
M
Berry
Susan A
SA
D000328:Adult; D000368:Aged; D000641:Ammonia / Q000097:blood*; D018592:Cross-Over Studies; D005260:Female; D005973:Glutamine / Q000031:analogs & derivatives / Q000097:blood; D005990:Glycerol / Q000031:analogs & derivatives / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D010648:Phenylacetates / Q000097:blood; D010654:Phenylbutyrates / Q000097:blood / Q000493:pharmacokinetics / Q000627:therapeutic use*; D056806:Urea Cycle Disorders, Inborn / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism*; D055815:Young Adult
D010648:Phenylacetates; D010654:Phenylbutyrates; D005973:Glutamine; D000641:Ammonia; C075773:4-phenylbutyric acid; C003089:phenylacetylglutamine; C025136:phenylacetic acid; D005990:Glycerol
Mol Genet Metab. 2009 Sep-Oct;98(1-2):195-7
19592285
Drug Metab Dispos. 2004 Jan;32(1):10-9
14709615
Acta Paediatr. 2008 Oct;97(10):1420-5
18647279
Adv Pediatr. 1996;43:127-70
8794176
Mol Genet Metab. 2008 Aug;94(4):397-402
18562231
Metabolism. 1993 Oct;42(10):1336-9
8412748
Pediatr Res. 1991 Feb;29(2):147-50
2014149
J Nutr. 2004 Oct;134(10 Suppl):2775S-2782S; discussion 2796S-2797S
15465784
N Engl J Med. 2007 May 31;356(22):2282-92
17538087